Status:
TERMINATED
Statin Treatment in Patients With Asthma
Lead Sponsor:
Queen's University
Collaborating Sponsors:
The Physicians' Services Incorporated Foundation
Ontario Lung Association
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Asthma is a chronic respiratory condition characterized by bronchial hyper-responsiveness secondary to abnormal inflammation of the lung. Steroids remain the most effective treatment for this conditio...
Detailed Description
Asthma affects 7 - 12 % of the population in North America and results in substantial morbidity and health care costs. Management of asthma is focused towards reducing airway inflammation through a co...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Moderate to severe asthma based on Canadian Asthma Consensus Report
- Objective evidence of airway hyper-responsiveness (reversible airflow obstruction or positive methacholine challenge in previous two years
- On chronic maintenance inhaled corticosteroid therapy.
Exclusion
- Asthma exacerbation within preceding 3 months necessitating any escalation of maintenance medications
- Chronic oral prednisone use
- Other respiratory, inflammatory and autoimmune disorder
- Abnormal baseline creatinine kinase, liver transaminases, or renal disease
- History of coronary artery disease, hyperlipidemia, or other condition requiring statin therapy
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00292201
Start Date
February 1 2006
End Date
June 1 2015
Last Update
September 16 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kingston General Hospital
Kingston, Ontario, Canada, K7L 2V6